Cargando…

Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers

The bipartite landscape of tumor cells and stromal cells determines a tumor’s response to treatment during disease management. In endometrial cancers (ECs), the mechanistic contribution of PD-L1/L2 and PD-1 signaling of the host’s tumor microenvironment (TME) (CAF and immune cells) in the context of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sulaiman, Raed, De, Pradip, Aske, Jennifer C., Lin, Xiaoqian, Dale, Adam, Koirala, Nischal, Gaster, Kris, Espaillat, Luis Rojas, Starks, David, Dey, Nandini
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342322/ https://www.ncbi.nlm.nih.gov/pubmed/37446260 http://dx.doi.org/10.3390/ijms241311079

Ejemplares similares

Patient-Derived Primary Cancer-Associated Fibroblasts Mediate Resistance to Anti-Angiogenic Drug in Ovarian Cancers
por: Sulaiman, Raed, et al.
Publicado: (2023)

Characterization and Clinical Relevance of Endometrial CAFs: Correlation between Post-Surgery Event and Resistance to Drugs
por: Sulaiman, Raed, et al.
Publicado: (2023)

A CAF-Based Two-Cell Hybrid Co-Culture Model to Test Drug Resistance in Endometrial Cancers
por: Sulaiman, Raed, et al.
Publicado: (2023)

Identification and Morphological Characterization of Features of Circulating Cancer-Associated Macrophage-like Cells (CAMLs) in Endometrial Cancers
por: Sulaiman, Raed, et al.
Publicado: (2022)

A Laboratory-Friendly CTC Identification: Comparable Double-Immunocytochemistry with Triple-Immunofluorescence
por: Sulaiman, Raed, et al.
Publicado: (2022)

Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity
por: Koirala, Nischal, et al.
Publicado: (2022)

Bête Noire of Chemotherapy and Targeted Therapy: CAF-Mediated Resistance
por: De, Pradip, et al.
Publicado: (2022)

Cancer-Associated Fibroblasts in Conversation with Tumor Cells in Endometrial Cancers: A Partner in Crime
por: Pradip, De, et al.
Publicado: (2021)

PD-1 inhibitors in endometrial cancer
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2017)

Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance
por: Mamat @ Yusof, Mohd Nazzary, et al.
Publicado: (2023)

Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer
por: Mo, Zhongfu, et al.
Publicado: (2016)

RAC1 Takes the Lead in Solid Tumors
por: De, Pradip, et al.
Publicado: (2019)

The impact of single agent PD-1 or PD-L1 inhibition on advanced endometrial cancers: meta-analysis
por: Kok, P.-S., et al.
Publicado: (2022)

PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression
por: Alkaabi, Duaa, et al.
Publicado: (2023)

Comprehensive Analysis of DNA Methylation and Transcriptome to Identify PD-1-Negative Prognostic Methylated Signature in Endometrial Carcinoma
por: Cao, Lu, et al.
Publicado: (2022)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies)
por: Ono, Ruriko, et al.
Publicado: (2019)

The development of endometrial hyperplasia in aged PD-1-deficient female mice
por: Guo, Guoning, et al.
Publicado: (2014)

Clinical Implication of PD-L1 Expression in Patients with Endometrial Cancer
por: Kim, Yeorae, et al.
Publicado: (2023)

Active RAC1 Promotes Tumorigenic Phenotypes and Therapy Resistance in Solid Tumors
por: De, Pradip, et al.
Publicado: (2020)

Magneto-nanosensor platform for probing low-affinity protein–protein interactions and identification of a low-affinity PD-L1/PD-L2 interaction
por: Lee, Jung-Rok, et al.
Publicado: (2016)

Cancer-Associated Fibroblast Functions as a Road-Block in Cancer Therapy
por: De, Pradip, et al.
Publicado: (2021)

Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCR
por: Dey, Nandini, et al.
Publicado: (2021)

Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
por: Nandini, Dey, et al.
Publicado: (2021)

Efficacy and Safety of PD-1/PD-L1 Inhibitor as Single-Agent Immunotherapy in Endometrial Cancer: A Systematic Review and Meta-Analysis
por: Mamat @ Yusof, Mohd Nazzary, et al.
Publicado: (2023)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

PD-L1 Expression in Endometrial Serous Carcinoma and Its Prognostic Significance
por: Zhang, Tao, et al.
Publicado: (2021)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 Pathway in Advanced, Recurrent Endometrial Cancer: A Scoping Review with SWOT Analysis
por: Johnson, Racheal Louise, et al.
Publicado: (2023)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
por: Litak, Jakub, et al.
Publicado: (2019)

A snapshot of the PD-1/PD-L1 pathway
por: Ghosh, Chinmoy, et al.
Publicado: (2021)

The PD-1:PD-L1 axis in Inflammatory Arthritis
por: Canavan, Mary, et al.
Publicado: (2021)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

PD-1/PD-L1 axis in organ fibrosis
por: Zhao, Youliang, et al.
Publicado: (2023)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis
por: Delgado, Ronan Jacques Rezende, et al.
Publicado: (2019)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cava2fu18ooag7micptrqfherj